Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug

Cambium Bio

11/07/2025 02:48

** Shares of Cambium Bio CMB.AX up as much as 30.2% to A$0.28, hitting highest level since April 24

** Regenerative medicine maker says it cleared US FDA's regulatory requirements to initiate patient dosing in its Phase 3 clinical trials of Elate Ocular which can be used to treat dry eye disease

** About 93,600 shares change hands, 18x the 30-day average

** Stock down 30% YTD, at current levels

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com;))